Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Pectosol
Leakage from unit packs caused by incompatibility of the bottle with the cap and an out-of-specification result for the “content in the package” parameter were found, which may affect safety of use until the end of shelf life. Potential effects: lack of treatment efficacy, possible irritation or complications if the product becomes contaminated.
Hemkortin-HC
The non-compliance indicated by OMCL may affect the quality of this product and the safety of its use, and therefore a risk to human health from keeping this batch of the medicinal product on the market cannot be excluded. Potential effects: lack of treatment efficacy, possible complications of the underlying disease.
Hemkortin-HC
The non-compliance in the parameter “zinc sulfate monohydrate content” indicated by OMCL may affect product quality and safety of use, and therefore a risk to human health cannot be excluded. Potential effects: lack of treatment efficacy, possible disease complications, skin reactions.
Septogard Plus
Exceeding the upper specification limit for “Related substances. Unspecified Cetylpyridinium impurity” was found, which may affect product quality and safety of use and may pose a risk to human health. Potential effects: impaired drug efficacy, adverse reactions, complications.
Septogard Plus
Exceeding the upper specification limit for the parameter “Related substances. Unspecified Cetylpyridinium impurity”, which may affect product quality and safety of use, therefore a risk to human health cannot be excluded. Potential effects: possible adverse effects and uncertainty regarding the product’s safety and efficacy.
Cefazolin TZF
The presence of brown liquid was found in some vials instead of white or almost white powder, indicating a quality defect of the product and possible impact on the safety of its use. Potential effects: lack of therapeutic efficacy, complications after intravenous or intramuscular administration, and unpredictable adverse reactions.
Cefazolin TZF
The presence of brown liquid was found in some vials instead of white or almost white powder, indicating a serious quality defect that may affect the product’s safety and efficacy. Potential effects: lack of treatment efficacy, infections, severe complications after intravenous administration.
Hemkortin-HC
The product does not meet quality requirements due to a negative test result for the parameter “zinc sulfate monohydrate content”; the level of this substance was found below the lower limit specified in the quality specification. Potential effects: possible decreased treatment efficacy and incomplete drug action.
Monover
A visible large piece of glass of about 1 cm moving inside the vial and glass particles on the walls and neck of the vial of a product administered intravenously were detected. Potential effects: damage to blood vessels, embolism, thrombotic complications, severe systemic complications, life‑threatening conditions.
Monover
A clearly visible large piece of glass and glass particles were confirmed in a vial of the product, and their presence in other vials of the batch cannot be reliably excluded, while the medicine is administered intravenously. Potential effects: embolic complications, vessel damage, severe systemic complications, life-threatening events.
Paracetamol Aflofarm
The above decisions were issued due to a justified suspicion that certain batches of the product did not meet established quality requirements, owing to the inability to obtain a homogeneous suspension and the presence of sediment at the bottom of the bottle despite repeated shaking. Potential effects: possible improper dosing and reduced treatment efficacy.
Osporil
The National Medicines Institute found, in batch ZD033, particles visible to the naked eye in two of twenty inspected vials of the infusion solution. Potential effects: embolism, inflammatory reactions, complications after intravenous administration.
Osporil
The National Medicines Institute found in this batch of the medicinal product the presence of particles visible to the naked eye in two of twenty tested vials, causing the batch to fail quality requirements for solution appearance. Potential effects: post-infusion complications, inflammatory reactions, embolism by particles, lack of safety during infusion.
Liść Senesu
It was found that the product does not meet the requirement for the parameter "presence of mould, live and dead pests and their residues"; NIL testing detected fragments of plastics, which are foreign components not allowed in the medicinal product. Potential effects: contamination with foreign bodies, risk of gastrointestinal injury, infection.
Liść Senesu
Fragments of plastics were detected in the tested sample of the batch and the product failed the requirement for the parameter “presence of mould, live and dead pests and their residues.” Potential effects: mechanical damage, irritation of the gastrointestinal tract, complications requiring medical intervention.
Risperidone Teva
Testing by the National Medicines Institute showed out-of-specification results for the release parameter and particle size analysis; the critical role of active substance release for the product’s efficacy and safety was emphasized. Potential effects: lack of treatment efficacy, possible adverse reactions or therapy-related complications.
Risperidone Teva
The National Medicines Institute found an out-of-specification result for the release parameter at specific time points and temperature; the product does not meet the established quality requirements. Potential effects: lack of therapeutic efficacy or unpredictable drug action.
Risperidone Teva
Testing by the National Medicines Institute (OMCL) showed an out-of-specification result for the release parameter at a defined time point and temperature, meaning the product does not meet quality requirements and concerns a critical parameter affecting the drug’s action. Potential effects: lack of therapeutic efficacy or its disturbance, possible clinical complications.
Polibiotic
The non-compliance in the parameters of dosage form and properties or water content may affect the quality of this product and the safety of its use, and therefore a risk to human health resulting from leaving these batches on the market cannot be excluded. Potential effects: reduced treatment effectiveness, possible skin irritation or other adverse skin reactions.
Polibiotic
The detected non-compliance in appearance, physical properties and water content may affect the product’s quality and safety of use; therefore a risk to human health cannot be excluded. Potential effects: lack of therapeutic efficacy or undesirable skin reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.